These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22951521)

  • 1. The effects of angiotensin receptor blockers vs. calcium channel blockers on the acute exercise-induced inflammatory and thrombotic response.
    Liakos CI; Vyssoulis GP; Michaelides AP; Chatzistamatiou EI; Theodosiades G; Toutouza MG; Markou MI; Synetos AG; Kallikazaros IE; Stefanadis CI
    Hypertens Res; 2012 Dec; 35(12):1193-200. PubMed ID: 22951521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R; Michailidis P
    Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antihypertensive therapy for refractory morning hypertension in patients on peritoneal dialysis].
    Kuriyama S; Otsuka Y; Iida R; Kobayashi S; Yamagishi H; Hosoya T
    Nihon Jinzo Gakkai Shi; 2005; 47(1):38-45. PubMed ID: 15754762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients.
    Naya M; Tsukamoto T; Morita K; Katoh C; Furumoto T; Fujii S; Tamaki N; Tsutsui H
    J Am Coll Cardiol; 2007 Sep; 50(12):1144-9. PubMed ID: 17868805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential impact of angiotensin receptor blockers and calcium channel blockers on arterial stiffness.
    Andreadis EA; Sfakianakis ME; Tsourous GI; Georgiopoulos DX; Fragouli EG; Katsanou PM; Tavoularis EI; Skarlatou MG; Marakomichelakis GE; Ifanti GK; Diamantopoulos EJ
    Int Angiol; 2010 Jun; 29(3):266-72. PubMed ID: 20502415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors.
    Agirbasli M; Cincin A; Baykan OA
    J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):22-6. PubMed ID: 18404606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Assessment of antihypertensive monotherapies effectiveness by home blood pressure self-measurement in hypertensive patients].
    Hanon O; Laroche P; Vidal JS; Pannier B; Postel-Vinay N; Vaisse B; Girerd X
    Ann Cardiol Angeiol (Paris); 2012 Jun; 61(3):218-23. PubMed ID: 22695025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
    Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial.
    Matsuzaki M; Ogihara T; Umemoto S; Rakugi H; Matsuoka H; Shimada K; Abe K; Suzuki N; Eto T; Higaki J; Ito S; Kamiya A; Kikuchi K; Suzuki H; Tei C; Ohashi Y; Saruta T;
    J Hypertens; 2011 Aug; 29(8):1649-59. PubMed ID: 21610513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria.
    Saito F; Fujita H; Takahashi A; Ichiyama I; Harasawa S; Oiwa K; Takahashi N; Otsuka Y; Uchiyama T; Kanmatsuse K; Kushiro T
    Hypertens Res; 2007 Jan; 30(1):39-47. PubMed ID: 17460370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of antihypertensive prescription and associated blood pressure control in Japan.
    Mori H; Ukai H; Yamamoto H; Saitou S; Hirao K; Yamauchi M; Umemura S
    Hypertens Res; 2006 Mar; 29(3):143-51. PubMed ID: 16755149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome.
    Nashar K; Nguyen JP; Jesri A; Morrow JD; Egan BM
    Am J Hypertens; 2004 Jun; 17(6):477-82. PubMed ID: 15177518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension.
    Andreadis EA; Tsourous GI; Marakomichelakis GE; Katsanou PM; Fotia ME; Vassilopoulos CV; Diamantopoulos EJ
    J Hum Hypertens; 2005 Jun; 19(6):491-6. PubMed ID: 15759025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.
    Oparil S; Weber M
    Postgrad Med; 2009 Mar; 121(2):25-39. PubMed ID: 19332960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients.
    Ishimitsu T; Kobayashi T; Honda T; Takahashi M; Minami J; Ohta S; Inada H; Yoshii M; Ono H; Matsuoka H
    Hypertens Res; 2005 Apr; 28(4):351-9. PubMed ID: 16138566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T; Fujimoto A; Nakao K; Saruta T;
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.